MCID: MLR004
MIFTS: 82

Malaria

Categories: Genetic diseases, Rare diseases, Infectious diseases

Aliases & Classifications for Malaria

MalaCards integrated aliases for Malaria:

Name: Malaria 54 38 12 50 56 52 41 3 42 14 69
Malaria, Cerebral 54 42 69
Cerebral Malaria 12 14
Induced Malaria 12 69
Malaria, Vivax, Protection Against 54
Malaria, Cerebral, Reduced Risk of 54
Malaria Due to G6pd Deficiency 54
Malaria, Protection Against 54
Susceptibility to Malaria 29
Malarial Encephalitis 12
Malaria Cerebral 52
Malaria, Severe 54
Cm 45

Characteristics:

Orphanet epidemiological data:

56
malaria
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 56  
Rare infectious diseases


Summaries for Malaria

OMIM : 54
Malaria, a major cause of child mortality worldwide, is caused by mosquito-borne hematoprotozoan parasites of the genus Plasmodium. Of the 4 species that infect humans, P. falciparum causes the most severe forms of malaria and is the major cause of death and disease. Although less fatal, P. malariae, P. ovale, and, in particular, P. vivax infections are major causes of morbidity. The parasite cycle involves a first stage in liver cells and a subsequent stage at erythrocytes, when malaria symptoms occur. A wide spectrum of phenotypes are observed, from asymptomatic infection to mild disease, including fever and mild anemia, to severe disease, including cerebral malaria, profound anemia, and respiratory distress. Genetic factors influence the response to infection, as well as disease progression and severity. Malaria is the strongest known selective pressure in the recent history of the human genome, and it is the evolutionary driving force behind sickle-cell disease (603903), thalassemia (see 141800), glucose-6-phosphatase deficiency (300908), and other erythrocyte defects that together constitute the most common mendelian diseases of humans (Kwiatkowski, 2005; Campino et al., 2006). (611162)

MalaCards based summary : Malaria, also known as malaria, cerebral, is related to dengue disease and hepatitis, and has symptoms including cognitive impairment, headache and thrombocytopenia. An important gene associated with Malaria is CD36 (CD36 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Artemether and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are hematopoietic system and cardiovascular system

NIH Rare Diseases : 50 malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. infection with malaria parasites may result in a wide variety of symptoms, ranging from absent or very mild symptoms to severe disease and even death. people who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. in general, malaria is a curable disease if diagnosed and treated promptly and correctly. treatment depends on many factors including disease severity, the species of malaria parasite causing the infection and the part of the world in which the infection was acquired. last updated: 5/12/2011

MedlinePlus : 41 malaria is a serious disease caused by a parasite. you get it when an infected mosquito bites you. malaria is a major cause of death worldwide, but it is almost wiped out in the united states. the disease is mostly a problem in developing countries with warm climates. if you travel to these countries, you are at risk. there are four different types of malaria caused by four related parasites. the most deadly type occurs in africa south of the sahara desert. malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. a blood test can diagnose it. it can be life-threatening. however, you can treat malaria with drugs. the type of drug depends on which kind of malaria you have and where you were infected. malaria can be prevented. when traveling to areas where malaria is found see your doctor for medicines that protect you wear insect repellent with deet cover up sleep under mosquito netting centers for disease control and prevention

CDC : 3 Malaria is a mosquito-borne disease caused by a parasite. People with malaria often experience fever, chills, and flu-like illness. Left untreated, they may develop severe complications and die. In 2015 an estimated 212 million cases of malaria occurred worldwide and 429,000 people died, mostly children in the African Region. About 1,700 cases of malaria are diagnosed in the United States each year. The vast majority of cases in the United States are in travelers and immigrants returning from countries where malaria transmission occurs, many from sub-Saharan Africa and South Asia.

Disease Ontology : 12 A parasitic protozoa infectious disease characterized as a vector-borne infectious disease caused by the presence of protozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle.

Wikipedia : 72 Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by parasitic... more...

Related Diseases for Malaria

Diseases related to Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 445)
id Related Disease Score Top Affiliating Genes
1 dengue disease 33.3 IFNG IL10 TLR9 TNF
2 hepatitis 32.1 G6PD HBB HP SLC4A1
3 lymphoma 32.0 IFNG IL10 TLR9 TNF
4 systemic lupus erythematosus 31.7 CR1 FCGR2A FCGR2B ICAM1 IFNG IL10
5 hemophagocytic lymphohistiocytosis 31.5 IFNG IL10 TNF
6 hemorrhagic fever 31.4 HBB HP
7 hepatitis b 31.2 CR1 IFNG IL10 TNF
8 plasmodium malariae malaria 12.4
9 plasmodium falciparum malaria 12.4
10 plasmodium vivax malaria 12.4
11 plasmodium ovale malaria 12.3
12 mixed malaria 12.2
13 malaria, mild 11.8
14 congenital myasthenic syndrome 11.7
15 blackwater fever 11.7
16 geniculate ganglionitis 11.7 CD36 CR1 FCGR2A G6PD HBB HP
17 capillary malformation-arteriovenous malformation 11.6
18 acute interstitial pneumonia 11.6 ACKR1 GYPA HP ICAM1 IFNG IL10
19 conduct disorder 11.6 ACKR1 G6PD ICAM1 IFNG IL10 TNF
20 hyperpigmentation of eyelid 11.6 HP ICAM1 IFNG IL10 TLR9 TNF
21 advanced sleep phase syndrome, familial, 1 11.5 ICAM1 IFNG IL10 NOS2 TLR9 TNF
22 acute chest syndrome 11.5 ICAM1 IFNG IL10 TLR9 TNF
23 lacrimal system cancer 11.5 HBB IFNG IL10 TLR9 TNF
24 ragweed sensitivity 11.5 ICAM1 IFNG IL10 NOS2 TNF
25 cockayne syndrome 11.5 HP IFNG IL10 TLR9 TNF
26 vagus nerve neoplasm 11.5 G6PD GYPA GYPB GYPC HBB SLC4A1
27 mucocutaneous leishmaniasis 11.5 IFNG IL10 NOS2 TLR9 TNF
28 degenerative disc disease 11.5 HP IFNG IL10 TLR9 TNF
29 discoid lupus erythematosus of eyelid 11.5 IFNG IL10 NOS2 TLR9 TNF
30 spindle cell hemangioma 11.5 FCGR2A ICAM1 IFNG IL10 TNF
31 dysphagia 11.5 ICAM1 IFNG IL10 TNF
32 prostate carcinoma in situ 11.5 IFNG IL10 NOS2 TLR9 TNF
33 hypospadias 11.5 ICAM1 IFNG IL10 TNF
34 chromoblastomycosis 11.5 CR1 ICAM1 NOS2 TNF
35 acute vascular insufficiency of intestine 11.5 ICAM1 IFNG TLR9 TNF
36 microscopic colitis 11.5 IFNG IL10 NOS2 TLR9 TNF
37 tularemia 11.5 IFNG IL10 TLR9 TNF
38 dehydration polycythemia 11.5 ICAM1 IL10 TLR9 TNF
39 churg-strauss syndrome 11.5 ICAM1 IFNG IL10 TNF
40 benign eccrine breast spiradenoma 11.5 ICAM1 IFNG IL10 TNF
41 motor peripheral neuropathy 11.5 IFNG IL10 TLR9 TNF
42 cerebellar disease 11.5 ICAM1 IFNG IL10 TNF
43 fuchs' heterochromic uveitis 11.5 ICAM1 IFNG TLR9 TNF
44 pulmonary embolism 11.5 FCGR2A IFNG IL10 TLR9 TNF
45 heart sarcoma 11.5 IFNG IL10 TLR9 TNF
46 early-onset zonular cataract 11.5 IFNG IL10 NOS2 TNF
47 gastric ulcer 11.5 IFNG IL10 TLR9 TNF
48 adult malignant mesenchymoma 11.5 G6PD HBB HP IFNG
49 scabies 11.5 ICAM1 IFNG IL10 TNF
50 opportunistic bacterial infectious disease 11.5 IFNG IL10 TLR9 TNF

Graphical network of the top 20 diseases related to Malaria:



Diseases related to Malaria

Symptoms & Phenotypes for Malaria

Clinical features from OMIM:

611162

Human phenotypes related to Malaria:

56 32 (show all 16)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cognitive impairment 56 32 frequent (33%) Frequent (79-30%) HP:0100543
2 headache 56 32 hallmark (90%) Very frequent (99-80%) HP:0002315
3 thrombocytopenia 56 32 frequent (33%) Frequent (79-30%) HP:0001873
4 anemia 56 32 hallmark (90%) Very frequent (99-80%) HP:0001903
5 respiratory distress 56 32 frequent (33%) Frequent (79-30%) HP:0002098
6 myalgia 56 32 frequent (33%) Frequent (79-30%) HP:0003326
7 fever 56 32 hallmark (90%) Very frequent (99-80%) HP:0001945
8 hyperbilirubinemia 56 32 frequent (33%) Frequent (79-30%) HP:0002904
9 gait imbalance 56 32 frequent (33%) Frequent (79-30%) HP:0002141
10 retinopathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0000488
11 nausea and vomiting 56 32 hallmark (90%) Very frequent (99-80%) HP:0002017
12 reduced consciousness/confusion 56 32 frequent (33%) Frequent (79-30%) HP:0004372
13 acute kidney injury 56 32 hallmark (90%) Very frequent (99-80%) HP:0001919
14 morphological abnormality of the central nervous system 56 32 hallmark (90%) Very frequent (99-80%) HP:0002011
15 elevated c-reactive protein level 56 32 hallmark (90%) Very frequent (99-80%) HP:0011227
16 abnormality of blood and blood-forming tissues 56 Frequent (79-30%)

UMLS symptoms related to Malaria:


angina pectoris, chest pain, edema, fever, pruritus, remittent fever

MGI Mouse Phenotypes related to Malaria:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 CD36 CISH FCGR2A FCGR2B G6PD HP
2 cardiovascular system MP:0005385 10.2 SLC4A1 TIRAP TNF CD36 FCGR2B G6PD
3 cellular MP:0005384 10.17 CD36 FCGR2B G6PD HP ICAM1 IFNG
4 homeostasis/metabolism MP:0005376 10.17 ACKR1 CD36 CISH FCGR2B G6PD HP
5 immune system MP:0005387 10.1 IL10 NOS2 SLC4A1 TIRAP TLR9 TNF
6 digestive/alimentary MP:0005381 10.01 CD36 FCGR2B ICAM1 IFNG IL10 NOS2
7 mortality/aging MP:0010768 9.77 TNF CD36 FCGR2A FCGR2B G6PD HP
8 liver/biliary system MP:0005370 9.7 CD36 FCGR2B HP IFNG IL10 NOS2
9 renal/urinary system MP:0005367 9.17 CD36 FCGR2B HP IFNG NOS2 SLC4A1

Drugs & Therapeutics for Malaria

Drugs for Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 369)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1 71963-77-4 119380 68911
2
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1 82186-77-4 6437380
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Artesunate Approved Phase 4,Phase 3,Phase 2,Phase 1 88495-63-0 6917864 5464098
5
Quinine Approved Phase 4,Phase 2,Phase 3,Phase 1 130-95-0 8549 3034034
6
Amodiaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 86-42-0 2165
7
Mefloquine Approved Phase 4,Phase 3,Phase 2,Phase 1 53230-10-7 4046
8
chloroquine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-05-7 2719
9
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-34-6 4908
10
Pyrimethamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-14-0 4993
11
Sulfadoxine Approved Phase 4,Phase 3,Phase 2,Phase 1 2447-57-6 17134
12
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
13
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3 54965-21-8 2082
14
Praziquantel Approved, Vet_approved Phase 4,Phase 3 55268-74-1 4891
15
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
16
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2 723-46-6 5329
17
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 738-70-5 5578
18
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 154598-52-4 64139
19
Nevirapine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 129618-40-2 4463
20
Rifampin Approved Phase 4,Phase 2,Phase 1 13292-46-1 5458213 5381226
21
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
22
Atovaquone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95233-18-4 74989
23
Proguanil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 500-92-5 4923
24
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
25
Doxycycline Approved, Investigational, Vet_approved Phase 4,Early Phase 1 564-25-0 54671203
26
Copper Approved Phase 4,Phase 3 7440-50-8 27099
27
Hydroxocobalamin Approved Phase 4,Phase 3 13422-51-0 11953898 5460373 44475014
28
Selenium Approved, Vet_approved Phase 4,Phase 3 7782-49-2
29
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
30
Benzocaine Approved Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
31
Morphine Approved, Investigational Phase 4 57-27-2 5288826
32
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80-08-0 2955
33
Ibuprofen Approved Phase 4 15687-27-1 3672
34
Lopinavir Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 192725-17-0 92727
35
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 155213-67-5 392622
36
Ivermectin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 70288-86-7 6474909 46936176
37
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 65140 441300
38
Lamivudine Approved, Investigational Phase 4,Phase 3,Early Phase 1 134678-17-4 60825
39
Zidovudine Approved Phase 4,Phase 3,Early Phase 1 30516-87-1 35370
40
Permethrin Approved, Investigational Phase 4,Phase 3 52645-53-1 40326
41
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
43
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 11103-57-4, 68-26-8 445354
45
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3 68-19-9 44176380
46
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1 59-67-6 938
47
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 1 98-92-0 936
48
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3 66-72-8 1050
49
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
50
Riboflavin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 83-88-5 493570

Interventional clinical trials:

(show top 50) (show all 1114)

id Name Status NCT ID Phase Drugs
1 In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure Unknown status NCT02590627 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
2 Targeted Indoor Residual Spraying Against Malaria Unknown status NCT02556242 Phase 4
3 Intravenous Artesunate and Malaria Unknown status NCT01805232 Phase 4 artesunate;Quinine
4 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
5 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
6 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
7 Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children Unknown status NCT00540202 Phase 4 artemether-lumefantrine;Oral quinine
8 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
9 Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal Unknown status NCT00712374 Phase 4 sulfadoxine-pyrimethamine plus amodiaquine
10 The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention Unknown status NCT01697852 Phase 4
11 The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy Unknown status NCT01906788 Phase 4 Artemether Lumefantrine;Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0;Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
12 The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau Unknown status NCT00137566 Phase 4 acetaminophen (paracetamol)
13 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
14 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
15 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
16 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
17 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
18 Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection Unknown status NCT02364583 Phase 4 Primaquine
19 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Unknown status NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
20 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
21 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
22 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
23 Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania Unknown status NCT02199951 Phase 4 Dihydroartemisinin and piperaquine
24 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
25 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
26 Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria Unknown status NCT01636895 Phase 4 Efficacy of suphladoxine/pyrimethamine as IPTp;Efficacy of suphladoxine/pyrimethamine as IPTp
27 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
28 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
29 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
30 Routine Iron Prophylaxis During Pregnancy Unknown status NCT00488579 Phase 4 Two policies of iron prophylaxis
31 Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine Unknown status NCT00168610 Phase 4 Vitamin A
32 Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts Completed NCT02536222 Phase 4
33 ANC & Malaria Diagnostic in Pregnancy Completed NCT01703884 Phase 4 ASAQ
34 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
35 The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level Completed NCT01907672 Phase 4
36 The Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities Completed NCT00351013 Phase 4
37 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
38 Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria Completed NCT01150344 Phase 4 Malarone (atovaquone + proguanil combination);RIAMET (artemether + LUMEFANTRIN combination)
39 The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children Completed NCT00550160 Phase 4 Amodiaquine plus Artesunate co-administration
40 Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component Completed NCT00680732 Phase 4 Chloroquine (CQ);Sulphadoxyne-pyrimethamine (SP)
41 Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana Completed NCT01651416 Phase 4 Artemether-lumefantrine combination;Dihydroartemisinin Piperaquine combination;Amodiaquine plus sulphadoxine-pyrimethamine combination
42 Home Management of Malaria and Pneumonia Completed NCT02151578 Phase 4
43 A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Malaria in Tanzania Completed NCT00146796 Phase 4
44 Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia Completed NCT01160809 Phase 4
45 Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania Completed NCT00687895 Phase 4
46 A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®) Completed NCT01256658 Phase 4 COA566
47 Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar Completed NCT00549003 Phase 4
48 CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi Completed NCT00125489 Phase 4 chloroquine sulfate;sulfadoxine/pyrimethamine
49 Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya Completed NCT01669941 Phase 4 IPTp-SP;IPTp-DP;ISTp-DP
50 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine

Search NIH Clinical Center for Malaria

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: malaria

Genetic Tests for Malaria

Genetic tests related to Malaria:

id Genetic test Affiliating Genes
1 Susceptibility to Malaria 29

Anatomical Context for Malaria

MalaCards organs/tissues related to Malaria:

39
Testes, T Cells, Brain, Liver, Endothelial, Skin, Lung

Publications for Malaria

Articles related to Malaria:

(show top 50) (show all 3703)
id Title Authors Year
1
Congenital Plasmodium falciparum Malaria in Washington, DC. ( 28077745 )
2017
2
Malaria Pathogenesis. ( 28533315 )
2017
3
Relationship between exposure to malaria and haemoglobin level of children 2-9 years old in low malaria transmission settings. ( 28522274 )
2017
4
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( 28850568 )
2017
5
Respiratory Complications of Plasmodium vivax Malaria: Systematic Review and Meta-Analysis. ( 28722625 )
2017
6
Insecticide-treated durable wall lining (ITWL): future prospects for control of malaria and other vector-borne diseases. ( 28532494 )
2017
7
Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda. ( 28089547 )
2017
8
Association between FcI^ receptor IIA, IIIA and IIIB genetic polymorphisms and susceptibility to severe malaria anemia in children in western Kenya. ( 28427365 )
2017
9
Testing times: trends in availability, price, and market share of malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2009 to 2015. ( 28526075 )
2017
10
Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda. ( 28320389 )
2017
11
Malaria-induced interferon-I^ drives the expansion of Tbethi atypical memory B cells. ( 28953967 )
2017
12
Therapeutic plasma exchange in the treatment of complicated Plasmodium falciparum malaria: A case report. ( 28922459 )
2017
13
Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in NaA^ve and Vaccinated Hosts. ( 28081253 )
2017
14
Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania. ( 28829723 )
2017
15
Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae. ( 28527688 )
2017
16
Entomological and parasitological parameters of malaria transmission in Douguia, Chad. ( 28947400 )
2017
17
Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. ( 28948924 )
2017
18
Association of CD40L gene polymorphism with severe Plasmodium falciparum malaria in Indian population. ( 28352049 )
2017
19
The association between malaria and malnutrition among under-five children in Shashogo District, Southern Ethiopia: a case-control study. ( 28081711 )
2017
20
Epidemiological analysis of 133 malaria cases in Shanxian county, Shandong Province, China. ( 28942829 )
2017
21
Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. ( 28867614 )
2017
22
Expression of cleaved caspase-3 in renal tubular cells in Plasmodium falciparum malaria patients. ( 26729581 )
2017
23
Role of Anopheles (Cellia) rufipes (Gough, 1910) and other local anophelines in human malaria transmission in the northern savannah of Cameroon: a cross-sectional survey. ( 28077167 )
2017
24
Counterfeit and substandard malaria drugs in Africa. ( 28948928 )
2017
25
Combating multidrug-resistant Plasmodium falciparum malaria. ( 28580606 )
2017
26
Household level spatio-temporal analysis of Plasmodium falciparum and Plasmodium vivax malaria in Ethiopia. ( 28427451 )
2017
27
TOLLIP gene variant is associated with Plasmodium vivax malaria in the Brazilian Amazon. ( 28288644 )
2017
28
Spatiotemporal epidemic characteristics and risk factor analysis of malaria in Yunnan Province, China. ( 28077125 )
2017
29
Performance of a High-Sensitivity Rapid Diagnostic Test for Plasmodium falciparum Malaria in Asymptomatic Individuals from Uganda and Myanmar and Naive Human Challenge Infections. ( 28820709 )
2017
30
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis. ( 28028628 )
2017
31
Pulmonary manifestation of Plasmodium falciparum malaria: Case reports and review of the literature. ( 28702342 )
2017
32
AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. ( 28916443 )
2017
33
Use of malaria RDTs in various health contexts across sub-Saharan Africa: a systematic review. ( 28521798 )
2017
34
Co-inheritance of glucose-6-phosphate dehydrogenase deficiency mutations and hemoglobin E in a Kachin population in a malaria-endemic region of Southeast Asia. ( 28531196 )
2017
35
A disrupted transsulphuration pathway results in accumulation of redox metabolites and induction of gametocytogenesis in malaria. ( 28091526 )
2017
36
The oxylipin and endocannabidome responses in acute phase Plasmodium falciparum malaria in children. ( 28886714 )
2017
37
Plasma metabolomics reveals membrane lipids, aspartate/asparagine and nucleotide metabolism pathway differences associated with chloroquine resistance in Plasmodium vivax malaria. ( 28813452 )
2017
38
Obesity and Diabetes as Risk Factors for Severe Plasmodium falciparum Malaria: Results From a Swedish Nationwide Study. ( 28510633 )
2017
39
The use of transgenic parasites in malaria vaccine research. ( 28525963 )
2017
40
Diagnosing congenital malaria in a high-transmission setting: clinical relevance and usefulness of P. falciparum HRP2-based testing. ( 28522856 )
2017
41
Underdiagnosed Complicated Plasmodium vivax Malaria in a Child: Need to Think. ( 28761494 )
2017
42
Using low-cost drones to map malaria vector habitats. ( 28088225 )
2017
43
Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure. ( 28835215 )
2017
44
Population genetic analysis of the DARC locus (Duffy) reveals adaptation from standing variation associated with malaria resistance in humans. ( 28282382 )
2017
45
Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of Plasmodium falciparum Malaria. ( 27847373 )
2017
46
Spatio-temporal analysis of malaria incidence in the Peruvian Amazon Region between 2002 and 2013. ( 28091560 )
2017
47
Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana. ( 28945794 )
2017
48
Comparative analysis of the safety and tolerability of fixed-dose artesunate/amodiaquine versus artemether/lumefantrine combinations for uncomplicated falciparum malaria in pregnancy: a randomized open label study. ( 28533699 )
2017
49
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or AlhydrogelAr in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. ( 28947345 )
2017
50
Increasing the potential for malaria elimination by targeting zoophilic vectors. ( 28091570 )
2017